Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

NARecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2026

Conditions
Breast CancerLymphoma
Interventions
DEVICE

PARASYM neuromodulation device

Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a preset position of one ear for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study.

DEVICE

PARASYM neuromodulation device

"Patients with breast cancer or lymphoma who have undergone chemotherapy for their disease, will have tests to determine heart function. Patients will be asked to use a handheld electrical unit (stimulator) at home to deliver vagus nerve stimulation (low level stimulation) to a different position of one ear compared to the experimental arm for a period of 1 hour for 14 days. After approximately 14 days, patients will have the same tests that they had at the beginning of the study."

Trial Locations (2)

73104

RECRUITING

Stephenson Cancer Center, Oklahoma City

74104

NOT_YET_RECRUITING

Stephenson Cancer Center- Tulsa, Tulsa

All Listed Sponsors
lead

University of Oklahoma

OTHER